Radiolabeled Somatostatin Analogues Therapy in Advanced Neuroendocrine Tumors: A Single Centre Experience

Peptide receptor therapies in neuroendocrine tumors

(2014) L. Bodei et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Serum Pancreastatin

(2012) Tetsuhide Ito et al.   PANCREAS

Gallium-68-DOTA-NOC PET/CT of Patients With Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Single-Center Study

(2011) Niraj Naswa et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

(2011) Jolanta Kunikowska et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study

(2011) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Future Directions in the Treatment of Neuroendocrine Tumors: Consensus Report of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting

(2011) Matthew H. Kulke et al.   JOURNAL OF CLINICAL ONCOLOGY

Radiopeptide Imaging and Therapy in Europe

(2011) V. Ambrosini et al.   JOURNAL OF NUCLEAR MEDICINE

Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors

(2010) Annibale Versari et al.   CLINICAL NUCLEAR MEDICINE

Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE

(2010) Irene Virgolini et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours

(2009) Irene J. Virgolini et al.   EUROPEAN JOURNAL OF CANCER

Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors

(2008) Lisa Bodei et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

(2008) James C. Yao et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

(2008) Dik J. Kwekkeboom et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of 68Ge/68Ga generator processing by chemical purification for routine clinical application of 68Ga-DOTATOC

(2008) Mattia Asti et al.   NUCLEAR MEDICINE AND BIOLOGY

Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations

(2008) Elisa Grassi et al.   NUCLEAR MEDICINE COMMUNICATIONS